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Abstract
Introduction Rheumatoid arthritis (RA) leads to progressive
destruction of articular cartilage. This study aimed to disclose
major mechanisms of antirheumatic drug action on human
chondrocytes and to reveal marker and pharmacological target
genes that are involved in cartilage dysfunction and
regeneration.
Methods An interactive in vitro cultivation system composed of
human chondrocyte alginate cultures and conditioned
supernatant of SV40 T-antigen immortalised human synovial
fibroblasts was used. Chondrocyte alginate cultures were
stimulated with supernatant of RA synovial fibroblasts, of healthy
donor synovial fibroblasts, and of RA synovial fibroblasts that
have been antirheumatically treated with disease-modifying
antirheumatic drugs (DMARDs) (azathioprine, gold sodium
thiomalate, chloroquine phosphate, and methotrexate),
nonsteroidal anti-inflammatory drugs (NSAIDs) (piroxicam and
diclofenac), or steroidal anti-inflammatory drugs (SAIDs)
(methylprednisolone and prednisolone). Chondrocyte gene
expression profile was analysed using microarrays. Real-time
reverse transcription-polymerase chain reaction and enzyme-
linked immunosorbent assay were performed for validation of
microarray data.
Results Genome-wide expression analysis revealed 110 RA-
related genes in human chondrocytes: expression of catabolic
mediators (inflammation, cytokines/chemokines, and matrix
degradation) was induced, and expression of anabolic
mediators (matrix synthesis and proliferation/differentiation) was
repressed. Potential marker genes to define and influence
cartilage/chondrocyte integrity and regeneration were
determined and include already established genes (COX-2,
CXCR-4, IL-1RN, IL-6/8, MMP-10/12, and TLR-2) and novel
genes (ADORA2A,  BCL2-A1,  CTGF,  CXCR-7,  CYR-61,
HSD11B-1, IL-23A, MARCKS, MXRA-5, NDUFA4L2, NR4A3,
SMS,  STS,  TNFAIP-2, and TXNIP). Antirheumatic treatment
with SAIDs showed complete and strong reversion of RA-
related gene expression in human chondrocytes, whereas
treatment with NSAIDs and the DMARD chloroquine phosphate
ADORA2A: adenosine A2A receptor; BCL2-A1: BCL2-related protein-A1; CCL-20: chemokine (C-C motif) ligand-20; COX: cyclooxygenase; CTGF: 
connective tissue growth factor; CXCR-4: chemokine (C-X-C motif) receptor-4; CYR-61: cysteine-rich angiogenic inducer-61; DMARD: disease-
modifying antirheumatic drug; ECM: extracellular matrix; ELISA: enzyme-linked immunosorbent assay; GAPDH: glyceraldehyde 3-phosphate dehy-
drogenase; GCOS: GeneChip Operating Software; GEO: Gene Expression Omnibus; HSD11B-1: hydroxysteroid (11-beta) dehydrogenase-1; IC20: 
20% inhibitory concentration; IL: interleukin; IL-1RN: interleukin-1 receptor antagonist; KEGG: Kyoto Encyclopaedia of Genes and Genomes; 
MARCKS: myristoylated alanine-rich protein kinase C substrate; MIP-3α: macrophage inflammatory protein-3-alpha; MMP: matrix metalloproteinase; 
MTS: 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium; MTX: methotrexate; MXRA-5: matrix-remodelling 
associated-5; NDSF: normal (healthy) donor synovial fibroblast; NDSFsn: supernatant of untreated normal (healthy) donor synovial fibroblast; 
NDUFA4L2: NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 4-like 2; NF-κB: nuclear factor-kappa-B; NR4A3: nuclear receptor subfamily 
4, group A, member 2; NSAID: nonsteroidal anti-inflammatory drug; PCR: polymerase chain reaction; PLA2G2A: phospholipase A2 group IIA; PTX3: 
pentraxin-related gene; RA: rheumatoid arthritis; RASF: rheumatoid arthritis synovial fibroblast; RASFsn: supernatant of untreated rheumatoid arthritis 
synovial fibroblast; RIPK2: receptor-interacting serine-threonine kinase 2; RMA: Robust Multichip Analysis; RSAD2: radical S-adenosyl methionine 
domain containing 2; RT-PCR: reverse transcription-polymerase chain reaction; SAID: steroidal anti-inflammatory drug; SDF-1: stromal cell-derived 
factor-1; SF: synovial fibroblast; STAT: signal transducer and activator of transcription; STS: steroid sulfatase; TGF-β: transforming growth factor-
beta; TLR: Toll-like receptor; TNF: tumour necrosis factor; TNFAIP-2: tumour necrosis factor-alpha-induced protein-2; TXNIP: thioredoxin interacting 
protein; VCAN: chondroitin sulfate proteoglycan 2; WISP2: WNT1 inducible signalling protein 2.Arthritis Research & Therapy    Vol 11 No 1    Andreas et al.
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had only moderate to minor effects. Treatment with the
DMARDs azathioprine, gold sodium thiomalate, and
methotrexate efficiently reverted chondrocyte RA-related gene
expression toward the 'healthy' level. Pathways of cytokine-
cytokine receptor interaction, transforming growth factor-beta/
Toll-like receptor/Jak-STAT (signal transducer and activator of
transcription) signalling and extracellular matrix receptor
interaction were targeted by antirheumatics.
Conclusions Our findings indicate that RA-relevant stimuli
result in the molecular activation of catabolic and inflammatory
processes in human chondrocytes that are reverted by
antirheumatic treatment. Candidate genes that evolved in this
study for new therapeutic approaches include suppression of
specific immune responses (COX-2,  IL-23A, and IL-6) and
activation of cartilage regeneration (CTGF and CYR-61).
Introduction
Progressive destruction of articular structures and chronic
inflammation of synovial joints are major pathophysiological
outcomes of rheumatoid arthritis (RA) [1]. As the disease
progresses, destruction of joint cartilage and, eventually, loss
of joint function cause excessive morbidity and disability. Cur-
rent approaches to drug therapy for RA focus predominantly
on the alleviation of inflammation, pain, and disease progres-
sion. Among the medicinal strategies, nonbiological disease-
modifying antirheumatic drugs (DMARDs) (for example, azathi-
oprine, gold sodium thiomalate, chloroquine phosphate, and
methotrexate [MTX]), steroidal anti-inflammatory drugs
(SAIDs) (for example, prednisolone and methylprednisolone),
and nonsteroidal anti-inflammatory drugs (NSAIDs) (for exam-
ple, piroxicam and diclofenac) have already been successfully
employed. The new group of biologics specifically targets
inflammatory cytokines (for example, tumour necrosis factor
[TNF] inhibitor etanercept) or receptors [2,3].
Despite recent progress in controlling inflammation, little carti-
lage repair has yet to be observed. Probably, suppression of
inflammation is not sufficient to restore joint structure and
function, and significant cartilage repair may be achieved only
by activation of local chondrocyte regeneration [4]. This under-
lines the need to identify distinct genes of RA-related chondro-
cyte dysfunction and to elucidate potential molecular
mechanisms, markers, and pharmacological targets in human
chondrocytes that might be involved in cartilage regeneration
and suppression of inflammation. Gene expression profiling
may be of help here to offer a better molecular understanding
of chondrocyte dysfunction and regeneration and to disclose
new therapeutic strategies [5].
Key mediators of joint destruction are RA synovial fibroblasts
(RASFs), which directly destroy cartilage by secreting matrix-
degrading enzymes [6,7]. Numerous studies on the gene
expression and protein secretion of RASFs have elucidated
potent diagnostic and therapeutic targets in RASFs that medi-
ate direct joint destruction and inflammation [8-13]. Recent
studies have offered insight into the mechanisms of drug
action; the molecular effects on RASFs following treatment
with frequently used antirheumatic drugs were determined by
genome-wide expression profiling [14].
Beyond direct cartilage destruction, RASFs maintain inflam-
mation in synovial joints and induce chondrocyte dysfunction
by releasing proinflammatory cytokines, in particular TNF-
alpha and interleukin (IL)-1-beta, and catabolic mediators
[6,15]. Inflammatory and catabolic stimuli from RASFs cause
indirect cartilage destruction; a disturbed tissue homeostasis
and a shift to catabolic mechanisms lead to suppressed matrix
synthesis and induce the production of degradative mediators
by chondrocytes, such as matrix metalloproteinases (MMPs),
prostaglandins, and nitric oxide [16,17]. Recently, we deter-
mined the RASF-induced expression profile in human
chondrocytes that disclosed genes that are related to carti-
lage destruction and that involve marker genes of inflamma-
tion/nuclear factor-kappa-B (NF-κB) signalling, cytokines,
chemokines and receptors, matrix degradation, and sup-
pressed matrix synthesis [18]. Although much is known about
RASFs as key mediators of cartilage destruction in RA,
researchers have scarcely analysed the molecular mecha-
nisms of cartilage regeneration induced by antirheumatic treat-
ment. Thus, the aim of this study was to establish an interactive
in vitro model that comprehensively illustrates the diversity of
antirheumatic drug effects on human chondrocytes and that
offers the opportunity for parallel and future drug testing. To
reveal marker and target genes for stimulation of cartilage/
chondrocyte regeneration and suppression of inflammation
was an additional goal of this study.
In the present study, human chondrocytes were cultured in
alginate beads and were stimulated with supernatant of
RASFs, healthy donor synovial fibroblasts (NDSFs), and drug-
treated RASFs, respectively. Genome-wide microarray analy-
sis was performed to determine RA-related gene expression
and antirheumatic drug response signatures in human
chondrocytes. Real-time reverse transcription-polymerase
chain reaction (RT-PCR) and enzyme-linked immunosorbent
assay (ELISA) were performed for validation of microarray
data.
Materials and methods
Cell culture
The local ethics committee of the Charité Berlin approved this
study.Available online http://arthritis-research.com/content/11/1/R15
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Human chondrocytes
Healthy human articular cartilage was obtained from knee con-
dyles of donors post mortem (n = 6 donors, age range of 39
to 74 years and mean age of 60 years) without known predis-
posing conditions for joint disorders. No macroscopic signs of
cartilage degradation or traumatic alterations were present.
Human chondrocytes were harvested as described previously
[19] and expanded in monolayer culture. Reaching conflu-
ence, chondrocytes were detached with 0.05% trypsin/
0.02% ethylenediaminetetraacetic acid (EDTA) (Biochrom
AG, Berlin, Germany) and subcultured at 10,000 cells per
centimetre squared. Reaching confluence again, human
chondrocytes were trypsinised, encapsulated in alginate
beads at 2 × 107 cells per millilitre in 1.5% (wt/vol) alginate
(Sigma-Aldrich, Munich, Germany) as described previously
[18], and three-dimensionally cultured for 14 days.
Synovial fibroblasts
Human SV40 T-antigen immortalised synovial fibroblasts
(SFs) were derived from primary synovial cells that were
obtained from synovial pannus tissue of an RA patient by sur-
gical synovectomy (RASFs, HSE cell line) and from normal
(healthy) donor synovial tissue following meniscectomy
(NDSFs, K4IM cell line). RASFs represent a prototype of acti-
vated SFs [20,21], and NDSFs represent healthy SFs [22].
Chondrocyte alginate beads and SFs were cultured sepa-
rately in RPMI 1640 (Biochrom AG) supplemented with 10%
human serum (German Red Cross, Berlin, Germany), 100 ng/
mL amphotericin B, 100 U/mL penicillin, 100 μg/mL strepto-
mycin (Biochrom AG), and 170 μM ascorbic acid 2 phosphate
(Sigma-Aldrich).
MTS cytotoxicity assay
Cytotoxic effects of antirheumatic drugs on RASFs were
determined by MTS (3-[4,5-dimethylthiazol-2-yl]-5-[3-car-
boxymethoxyphenyl]-2-[4-sulfophenyl]-2H-tetrazolium) cell
proliferation assay (Promega GmbH, Mannheim, Germany).
SFs were seeded at a density of 3 × 103 cells per well into 96-
well plates in triplicate. Reaching 70% confluence, medium
was replaced by phenol red-free RPMI 1640 medium (Bio-
chrom AG) containing azathioprine (0 to 400 μg/mL, Imurek;
GlaxoSmithKline GmbH, Munich, Germany), gold sodium thi-
omalate (0 to 100 μg/mL, Tauredon; Altana Pharma Deutsch-
land GmbH, Konstanz, Austria), chloroquine phosphate (0 to
400 μg/mL, Resochin; Bayer Vital GmbH, Leverkusen, Ger-
m a n y ) ,  M T X  ( 0  t o  1 0  μg/mL, Methotrexat; Medac GmbH,
Hamburg, Germany), piroxicam (0 to 400 μg/mL, pirox-ct; CT-
Arzneimittel GmbH, Berlin, Germany), diclofenac (0 to 200
μg/mL, Diclofenac; ratiopharm GmbH, Ulm, Germany), meth-
ylprednisolone (0 to 2,000 μg/mL, Urbason; Aventis Pharma
Deutschland GmbH, Frankfurt am Main, Germany), or pred-
nisolone (0 to 2,000 μg/mL, Solu Decortin H; Merck, Darm-
stadt, Germany). Control cultures were maintained in phenol
red-free medium without drug supplementation. Following 48
hours of drug treatment, MTS assay was performed according
to the instructions of the manufacturer. Drug concentrations
that resulted in 80% metabolic activity of RASFs compared
with untreated controls (20% inhibitory concentration [IC20])
were determined. Drug-treated synovial cells were assessed
microscopically for typical fibroblast-like morphology.
Experimental setup
Figure 1 illustrates the setup of the conducted experiments.
Medium of subconfluent NDSFs and RASFs was conditioned
for 48 hours. RASFs were incubated for 48 hours with medium
containing IC20 of azathioprine, gold sodium thiomalate, chlo-
roquine phosphate, MTX, piroxicam, diclofenac, methylpred-
nisolone, and prednisolone, respectively. Cartilage-like
alginate beads (n = 6 donors) were stimulated for 48 hours
with conditioned supernatant of untreated NDSFs (NDSFsn),
of untreated RASFs (RASFsn), and of drug-treated RASFs.
Following interactive cultivation, isolation of total RNA was
performed and supernatants were collected. Genome-wide
expression profiling, real-time RT-PCR, and ELISA were con-
ducted.
RNA isolation and genome-wide expression profiling
Stimulated human chondrocytes were harvested from alginate
beads as described previously [18]. In brief, alginate beads
were solubilised on ice and human chondrocytes were har-
vested by centrifugation. Total RNA was isolated using an
RNeasy Mini Kit (Qiagen, Hilden, Germany) in accordance
with the instructions of the manufacturer. In addition, protein-
ase K and DNase I digestions were performed. Isolation of
total RNA was performed for each donor separately (n = 6
donors). Equal amounts of total RNA from three different
donors were pooled, yielding two different experimental
groups (two pools with three donors for each pool) for
untreated controls and for each drug treatment. Pooled RNA
was used for microarray analysis and for real-time RT-PCR.
Microarray analysis was performed using the oligonucleotide
microarray HG U133A GeneChip (Affymetrix, High Wycombe,
UK) in accordance with the recommendations of the manufac-
turer. In brief, 2.5 μg of pooled RNA was used to generate
biotin-labelled cRNA by cDNA synthesis and in vitro transcrip-
tion. Next, 10 μg (50 μg/mL) of fragmented cRNA was hybrid-
ised to the oligonucleotide microarrays, and GeneChips were
washed, stained, and scanned as recommended.
Microarray data mining
Raw gene expression data analyses were processed using (a)
GeneChip Operating Software (GCOS) (Affymetrix) and (b)
Robust Multichip Analysis (RMA) [23]. Genes were differen-
tially expressed if regulated greater than or equal to twofold or
less than or equal to twofold as determined by both GCOS
and RMA statistical analyses in both experimental groups (two
pools with three donors for each pool). Microarray data mining
was performed in accordance with the procedure described in
Table 1. First, RA-related genes and pathways were identifiedArthritis Research & Therapy    Vol 11 No 1    Andreas et al.
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Figure 1
Experimental setup Experimental setup. Medium of subconfluent normal (healthy) donor synovial fibroblasts (NDSFs) and rheumatoid arthritis synovial fibroblasts 
(RASFs) was conditioned for 48 hours. RASFs were incubated for 48 hours with medium containing a 20% inhibitory concentration of antirheumatic 
drugs. Cartilage-like alginate beads (n = 6 donors) were stimulated for 48 hours with conditioned supernatant of untreated RASFs, untreated 
NDSFs, and drug-treated RASFs, respectively. Following interactive cultivation, isolation of total RNA was performed and chondrocyte supernatants 
were collected. Genome-wide expression profiling, real-time reverse transcription-polymerase chain reaction (RT-PCR), and enzyme-linked immuno-
sorbent assay (ELISA) analysis were performed. 3D, three-dimensional; SF, synovial fibroblast.
Table 1
Microarray data mining
Analysis Finding
RA-related genes in human chondrocytes differentially expressed in 
human chondrocytes that were stimulated with supernatant of RASFs 
versus NDSF stimulation
- 110 pharmacological marker genes and relevant pathways of RA-
related chondrocyte dysfunction
KEGG pathway analysis
Antirheumatic drug response signatures in human chondrocytes - Mechanism of drug action
Differential expression of RA-related genes in human chondrocytes due 
to antirheumatic treatment of RASFs (stimulation of human 
chondroctyes with supernatant of drug-treated RASFs versus 
stimulation with supernatant of untreated RASFs)
- 94 pharmacological marker genes and relevant pathways for 
stimulation of cartilage regeneration and suppression of inflammation
Hierarchical clustering analysis, principal components analysis, and 
KEGG pathway analysis
Validation of microarray data - Microarray data were confirmed for selected genes/proteins
- Real-time reverse transcription-polymerase chain reaction
- Enzyme-linked immunosorbent assay
KEGG, Kyoto Encyclopaedia of Genes and Genomes; NDSF, healthy donor synovial fibroblast; RA, rheumatoid arthritis; RASF, rheumatoid 
arthritis synovial fibroblast.Available online http://arthritis-research.com/content/11/1/R15
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in human chondrocytes. For this purpose, differentially
expressed genes were determined between RASFsn-stimu-
lated chondrocytes ('diseased' status) and NDSFsn-stimu-
lated chondrocytes ('healthy' status). These genes were
considered to be relevant to chondrocyte dysfunction in RA.
Next, expression levels of the determined RA-related genes
were analysed following treatment with antiheumatic drugs.
The antirheumatic drug response signatures were supposed
to comprise all RA-related genes that were reverted by treat-
ment from the 'diseased' expression level in RASFsn-stimu-
lated chondrocytes toward the 'healthy' level in NDSFsn-
stimulated chondrocytes. These marker genes were consid-
ered to be relevant for drug-induced cartilage/chondrocyte
regeneration and suppression of inflammation.
To visualise and to compare the RA-related chondrocyte gene
expression pattern for the different therapies, hierarchical clus-
ter and principal components analyses with normalised mean
gene expression values were performed with Genesis 1.7.2
software (Graz University of Technology, Institute for Genom-
ics and Bioinformatics, Graz, Austria) [24]. Functional annota-
tion was determined according to reports from the literature.
Pathway analysis was performed to disclose relevant mecha-
nisms that are related to chondrocyte dysfunction in RA and to
drug-induced chondrocyte regeneration and suppression of
inflammation. For this purpose, expression levels of RA-related
genes were submitted to the Database for Annotation, Visual-
isation, and Integrated Discovery (DAVID) and to the Kyoto
Encyclopaedia of Genes and Genomes (KEGG) database
[25,26]. Determined KEGG pathways showed a P value of
less than or equal to 0.05. Microarray data have been depos-
ited in the National Center for Biotechnology Information Gene
Expression Omnibus (GEO) and are accessible through GEO
series accession number [GEO:GSE12860].
Real-time reverse transcription-polymerase chain 
reaction
Expression of selected genes was verified by real-time RT-
PCR. Pooled total RNA (two pools with three donors for each
pool) was reverse-transcribed with an iScript cDNA synthesis
kit as recommended by the manufacturer (Bio-Rad Laborato-
ries GmbH, Munich, Germany). TaqMan real-time RT-PCR
was performed in triplicates in 96-well optical plates on an ABI
Prism 7700 Sequence Detection System (Applied Biosys-
tems, Darmstadt, Germany) using primer and probe sets from
Applied Biosystems for cyclooxygenase 2 (COX-2,
Hs00153133_m1), chemokine (C-X-C motif) receptor 4
(CXCR-4, assay ID Hs00607978_s1), thioredoxin interacting
protein (TXNIP, Hs00197750_m1), steroid sulfatase (STS,
Hs00165853_m1), and glyceraldehyde 3-phosphate dehy-
drogenase (GAPDH, Hs99999905_m1). The endogenous
expression level of GAPDH  was used to normalise gene
expression levels, and relative quantification of gene expres-
sion was given as a percentage of GAPDH.
Enzyme-linked immunosorbent assay
Supernatants were collected and stored at -20°C. Levels of IL-
6, CXCL-8 (IL-8), and CCL-20 (macrophage inflammatory pro-
tein-3-alpha, or MIP-3α) were measured using quantitative
sandwich enzyme immunoassay (ELISA) in accordance with
the recommended procedures of the manufacturer (RayBio-
tech, Inc., Norcross, GA, USA). Background signals of SF
supernatants were subtracted, and protein concentration was
normalised to one chondrocyte alginate bead. For statistical
analysis, t test (normal distribution) or Mann-Whitney rank sum
test (non-normal distribution) was applied using Sigmastat
software (Systat Software, San Jose, CA, USA).
Results
Cytotoxicity of antirheumatic drugs on rheumatoid 
arthritis synovial fibroblasts
For standardisation of this study and to ensure cell viability and
drug response, the effective doses of the examined antirheu-
matic drugs on RASFs were determined. By means of cytotox-
icity assays, drug concentrations that resulted in 80% vitality
of RASFs following 48 hours of drug exposure compared with
untreated controls were identified. The following IC20 values
were determined: 10 μg/mL azathioprine, 5 μg/mL gold
sodium thiomalate, 50 μg/mL chloroquine phosphate, 0.2 μg/
mL MTX, 25 μg/mL piroxicam, 75 μg/mL diclofenac, 1 μg/mL
methylprednisolone, and 1 μg/mL prednisolone (data not
shown). The typical fibroblast-like morphology of RASFs was
maintained following treatment with these drug concentrations
(data not shown). The respective IC20 drug concentrations
were applied for antirheumatic treatment of RASFs in the sub-
sequent experiments.
Rheumatoid arthritis-related gene expression in human 
chondrocytes
For identification of RA-related changes, differentially
expressed genes were determined in human chondrocytes
that have been stimulated with supernatant of RASFs ('dis-
eased' status) compared with NDSF stimulation ('healthy' sta-
tus). This revealed 110 genes that are involved in
inflammation/NF-κB signalling pathway, cytokines/chemok-
ines and receptor interaction, immune response, proliferation/
differentiation, matrix degradation, and suppressed matrix syn-
thesis (Additional data files 1 and 2). Genes that are known to
be associated with immunological processes (inflammation
[for example, ADORA2A, IL-1RN, TLR-2, and COX-2] and
cytokines/chemokines [for example, IL-23A, CXCR-4/7, CCL-
20, and CXCL-1–3/8]) or catabolic mechanisms (matrix deg-
radation [for example, MMP-10/12]) were induced, and ana-
bolic mediators (matrix synthesis [for example, VCAN] and
proliferation/differentiation [for example, WISP-2 and CTGF])
were repressed. Thus, these 110 genes demonstrated a dis-
turbed chondrocyte homeostasis and respective genes were
considered to be relevant for chondrocyte dysfunction in RA.Arthritis Research & Therapy    Vol 11 No 1    Andreas et al.
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Antirheumatic drug response signatures in human 
chondrocytes and genes to define and influence 
cartilage integrity and regeneration
For identification of major mechanisms and molecular markers
and targets of chondrocyte regeneration, RASFs were treated
with different antirheumatic drugs and conditioned superna-
tants were used for chondrocyte stimulation. The antirheu-
matic drug response signatures were investigated for the
determined 110 RA-related genes in human chondrocytes to
characterise the drug-related reversion from the 'diseased'
expression level toward the 'healthy' level. Expression of 94
genes was reverted by at least one type of treatment (Addi-
tional data file 1, Figures 2 and 3). Response to treatment sug-
gests that these genes also reflect molecular processes
relevant for therapeutic interference to maintain and regener-
ate cartilage. Apart from known marker genes of cartilage/
chondrocyte integrity and regeneration (COX-2, CXCR-4, IL-
1RN, IL-6/8, MMP-10/12, and TLR-2), numerous novel mark-
ers, including ADORA2A, BCL2-A1, CTGF, CXCR-7, CYR-
61,  HSD11B-1,  IL-23A,  MARCKS,  MXRA-5,  NDUFA4L2,
NR4A3, SMS, STS, TNFAIP-2, and TXNIP, were determined.
On the contrary, the expression of the 16 remaining RA-related
chondrocyte genes was not reverted by treatment with any of
the antirheumatic drugs examined (Additional data file 2).
These genes include phospholipase A2 group IIA
(PLA2G2A), chondroitin sulfate proteoglycan 2 (VCAN), and
pentraxin-related gene (PTX3).
Treatment with disease-modifying antirheumatic drugs
When exposing RASFs to DMARDs (Figure 2), azathioprine,
gold sodium thiomalate, and MTX efficiently reverted the RA-
induced molecular changes in chondrocytes toward the
'healthy' level; in particular, genes related to inflammation/NF-
κB pathway, cytokine/chemokine activity, immune response,
proliferation/differentiation,  and matrix remodelling were
involved. In contrast, only a minority of RA-related changes
were reverted by treatment with chloroquine phosphate. Thus,
to reconstitute the molecular signature of cartilage/chondro-
Figure 2
Disease-modifying antirheumatic drug (DMARD) response signatures in human chondrocytes Disease-modifying antirheumatic drug (DMARD) response signatures in human chondrocytes. Centroid view (fold change) of rheumatoid arthritis 
(RA)-related chondrocyte gene expression following treatment of rheumatoid arthritis synovial fibroblasts (RASFs) with DMARDs azathioprine, gold 
sodium thiomalate, chloroquine phosphate, and methotrexate. Black bars represent the RA-related gene expression in human chondrocytes (differ-
ential gene expression of RASFsn-stimulated chondrocytes versus NDSFsn stimulation). Grey bars represent the DMARD response signatures in 
human chondrocytes (differential gene expression of human chondrocytes stimulated with drug-treated RASFs compared with stimulation with 
untreated RASFs). Azathioprine, gold sodium thiomalate, and methotrexate treatment of RASFs resulted in a reverted gene expression of the majority 
of RA-related genes in human chondrocytes. In contrast, RASF treatment with chloroquine phosphate had only minor effects. NDSFsn, supernatant 
of untreated normal (healthy) donor synovial fibroblast; NF-κB, nuclear factor-kappa-B; RASFsn, supernatant of untreated rheumatoid arthritis syno-
vial fibroblast.Available online http://arthritis-research.com/content/11/1/R15
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cytes, azathioprine, gold sodium thiomalate, or MTX seem to
be much more effective than chloroquine phosphate.
Treatment with nonsteroidal anti-inflammatory drugs
Treatment of RASFs with NSAIDs (piroxicam and diclofenac)
reverted the expression of approximately 50% of the RA-
induced changes in human chondrocytes (Figure 3a). Expo-
sure of RASFs to piroxicam predominantly regulated expres-
sion of genes in chondrocytes that are related to inflammation/
NF-κB pathway and cytokines/chemokines. In contrast,
diclofenac treatment reverted expression of genes predomi-
nantly associated with immune response. However, numerous
other RA-induced changes were not affected by NSAID treat-
ment, and thus treatment of RASFs with NSAIDs showed only
moderate effects on chondrocytes.
Treatment with steroidal anti-inflammatory drugs
After treatment of RASFs with SAIDs (methylprednisolone and
prednisolone), a nearly complete and very efficient reversion
from the 'diseased' toward the 'healthy' level was determined
in human chondrocytes (Figure 3b). Thus, genes of all six func-
tional annotation groups were involved and several genes
(Bcl2-related protein A1 [BCL2-A1], COX-2, chemokine (C-
X-C motif) ligand-8 [CXCL-8/IL-8], and IL-6) were reverted
even beyond the level of controls stimulated with NDSF super-
natant. In addition, methylprednisolone and prednisolone treat-
ment of RASFs showed very similar effects on the RA-related
gene expression pattern in human chondrocytes.
Quantification of drug effects
The effect of antirheumatic drugs on human chondrocytes was
very different, ranging from a strong reversion (SAIDs) to minor
Figure 3
Nonsteroidal anti-inflammatory drug (NSAID) and steroidal anti-inflammatory drug (SAID) response signatures in human chondrocytes Nonsteroidal anti-inflammatory drug (NSAID) and steroidal anti-inflammatory drug (SAID) response signatures in human chondrocytes. Centroid 
view (fold change) of rheumatoid arthritis (RA)-related chondrocyte gene expression following treatment of rheumatoid arthritis synovial fibroblasts 
(RASFs) with (a) NSAIDs piroxicam and diclofenac and (b) SAIDs methylprednisolone and prednisolone. Black bars represent the RA-related gene 
expression in human chondrocytes (differential gene expression of RASFsn-stimulated chondrocytes versus NDSFsn stimulation). Grey bars repre-
sent the NSAID/SAID response signatures in human chondrocytes (differential gene expression of human chondrocytes stimulated with drug-
treated RASFs compared with stimulation with untreated RASFs). Whereas piroxicam mainly influenced the expression of RA-related genes involved 
in inflammation/nuclear factor-kappa-B (NF-κB) and cytokines/chemokines, diclofenac predominantly had an impact on the expression of genes 
associated with immune response. Expression of numerous RA-related genes was not influenced by NSAID treatment. In contrast, SAID treatment 
led to an almost complete reversion of chondrocyte RA-related gene expression. The expression of distinct genes involved in inflammation and 
cytokines/chemokines (BCL2-A1, COX-2, CXCL-8/IL-8, and IL-6) was strongly repressed. NDSFsn, supernatant of untreated healthy donor syno-
vial fibroblast; RASFsn, supernatant of untreated rheumatoid arthritis synovial fibroblast.Arthritis Research & Therapy    Vol 11 No 1    Andreas et al.
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Figure 4
Hierarchical clustering and principal components analyses of rheumatoid arthritis (RA)-related chondrocyte gene expression levels in response to  antirheumatic treatment Hierarchical clustering and principal components analyses of rheumatoid arthritis (RA)-related chondrocyte gene expression levels in response to 
antirheumatic treatment. Hierarchical clustering and principal components analyses of mean expression values of RA-related chondrocyte genes 
were performed for the 'diseased' status (RASFsn-stimulated), the 'healthy' status (NDSFsn-stimulated), and the drug-treated 'diseased' status 
(RASFsn antirheumatic drug-stimulated). (a) Hierarchical clustering analysis (tree plot). Colours represent relative levels of gene expression: bright 
red indicates the highest level of expression, and bright green indicates the lowest level of expression. Hierarchical clustering analysis showed that 
treatment with disease-modifying antirheumatic drugs (DMARDs) methotrexate, azathioprine, and gold sodium thiomalate resulted in chondrocyte 
expression patterns that were closely related to the 'healthy' status. Chloroquine phosphate and diclofenac treatment had only minor effects because 
they clustered together with RASFsn-stimulated chondrocytes ('diseased' status). Steroidal anti-inflammatory drug (SAID) treatment reverted the 
expression of some RA-related genes even beyond the 'healthy' level. (b) Principal components analysis (three-dimensional plot) demonstrates the 
quantitative differences of drug response. DMARDs, except for chloroquine phosphate, and SAIDs reduced the distance between RASFsn and 
NDSFsn stimulation to a minor difference, whereas DMARDs located toward the 'diseased' status and SAIDs reverted beyond the location of the 
'healthy' status. aza, azathioprine; chloro, chloroquine phosphate; diclo, diclofenac; gold, gold sodium thiomalate; mpred, methylprednisolone; MTX, 
methotrexate; NDSFsn, supernatant of untreated healthy donor synovial fibroblast; NF-κB, nuclear factor-kappa-B; piro, piroxicam; pred, pred-
nisolone; RASFsn, supernatant of untreated rheumatoid arthritis synovial fibroblast.Available online http://arthritis-research.com/content/11/1/R15
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effects (chloroquine phosphate). To directly compare and to
visualise these effects, hierarchical cluster analysis and princi-
pal components analysis were performed (Figure 4). Chloro-
quine phosphate and diclofenac had only minor effects and
clustered close to the 'diseased' status of untreated RASFsn-
stimulated chondrocytes. In contrast, the DMARDs azathio-
prine, gold sodium thiomalate, and MTX were much more
effective, reverted most of the RA-induced signature, and
revealed similar quantitative effects. SAIDs finally displayed
highest potency and reverted expression of many genes to
'healthy' levels or even beyond.
Pathways to stimulate chondrocyte regeneration
The KEGG database was retrieved for the pathways to which
the 110 RA-related genes belong. These pathways comprised
cytokine-cytokine receptor interaction, Jak-STAT (signal trans-
ducer and activator of transcription) signalling, Toll-like recep-
tor (TLR) signalling, transforming growth factor-beta (TGF-β)
signalling, focal adhesion, extracellular matrix (ECM) receptor
interaction, ether lipid metabolism, and cell communication.
Drug-specific dominance of action is summarised in Additional
data file 3. The DMARDs azathioprine and gold sodium thi-
omalate, the NSAID piroxicam, and the SAIDs prednisolone
and methylprednisolone targeted numerous RA-related path-
ways involved in cytokine/chemokine activity (cytokine-
cytokine receptor interaction and Jak-STAT signalling), matrix
remodelling (focal adhesion, TGF-β signalling, and ECM
receptor interaction), and lipid metabolism (ether lipid metab-
olism, biosynthesis of steroids, and arachidonic acid metabo-
lism). In contrast, chloroquine phosphate and diclofenac had
only minor effects on RA-related pathways.
Validation of microarray data by real-time reverse 
transcription-polymerase chain reaction and enzyme-
linked immunosorbent assay
To confirm the expression profiles that were determined by
microarray analysis, expression of selected genes was verified
by real-time RT-PCR (Figure 5) and ELISA (Figure 6). For val-
idation by PCR, two genes with increased expression and two
genes with decreased expression after stimulation with RASF
Figure 5
Real-time reverse transcription-polymerase chain reaction (RT-PCR) expression analysis of selected rheumatoid arthritis (RA)-related chondrocyte  genes in response to antirheumatic treatment Real-time reverse transcription-polymerase chain reaction (RT-PCR) expression analysis of selected rheumatoid arthritis (RA)-related chondrocyte 
genes in response to antirheumatic treatment. Real-time RT-PCR confirmed the expression profiles of cyclooxygenase-2 (COX-2), chemokine (C-X-
C motif) receptor-4 (CXCR-4), thioredoxin interacting protein (TXNIP), and steroid sulfatase (STS) following treatment with methotrexate (disease-
modifying antirheumatic drug [DMARD]), diclofenac (nonsteroidal anti-inflammatory drug [NSAID]), and prednisolone (steroidal anti-inflammatory 
drug [SAID]). Expression of COX-2 and CXCR-4 was induced in RASFsn-stimulated chondrocytes and repressed again following antirheumatic 
treatment. Expression of TXNIP and STS was repressed in RASFsn-stimulated chondrocytes and induced again following antirheumatic treatment. 
Expression of selected genes was calculated as the percentage of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) expression. The mean of 
each triplicate well is plotted, and the error bars represent the standard deviation. RASFsn, supernatant of untreated rheumatoid arthritis synovial 
fibroblast.Arthritis Research & Therapy    Vol 11 No 1    Andreas et al.
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supernatant were selected. COX-2 as a product involved in
proinflammatory actions of the chondrocyte itself was selected
because of its broad and differential responsiveness to all
drugs, its potent downregulation by glucocorticoids, and its
exceptional role in current treatment strategies of rheumatic
diseases. CXCR-4 as the second upregulated gene with dif-
ferential response to all drugs is known to sensitise chondro-
cytes for MMP secretion upon stromal cell-derived factor-1
(SDF-1) stimulation and to be involved in chondrocyte death
induction by pathological concentrations of SDF-1 [27,28].
Both genes are well established in chondrocyte pathology and
validate the relevance of the in vitro model. The two genes
TXNIP and STS are both downregulated after stimulation with
RASF supernatant and are not yet described in RA-related
cartilage destruction. TXNIP  is involved in oxidative stress
metabolism by inhibiting thioredoxin and thus represents a
marker for the potency to response to oxidative stress. STS is
involved in the biosynthesis of steroids and may be involved in
processes of growth and cartilage maturation [29].
PCR validation experiments were performed for representative
antirheumatic drugs from the group of DMARDs (MTX),
NSAIDs (diclofenac), and SAIDs (prednisolone). Upregulation
of COX-2 and CXCR-4 in chondrocytes by RASFsn stimula-
tion and downregulation upon treatment with MTX, diclofenac,
and prednisolone were confirmed. Similarly, regulation of
TXNIP and STS as identified by microarray analysis with a
decrease after RASFsn stimulation and an increase after treat-
ment with MTX, diclofenac, and prednisolone was also con-
firmed by PCR.
ELISA analysis of the supernatants was performed to validate
the expression profiles of IL-6, the chemokine (C-X-C motif)
ligand-8 (CXCL-8/IL-8), and the chemokine (C-C motif) lig-
and-20  (CCL-20/MIP-3α) on the protein level (Figure 6).
Cytokines/chemokines are potent mediators of inflammation,
and increased chondrocyte expression upon proinflammatory
stimulus has been reported. However, a drug-induced sup-
pression of cytokine/chemokine secretion from human
chondrocytes has not yet been described and thus was
selected for validation.
The protein secretions of IL-6, CXCL-8/IL-8, and CCL-20/
MIP-3α were increased in RASFsn-stimulated chondrocytes
compared with NDSFsn stimulation. Consistent with the
microarray data, treatment with azathioprine, gold sodium thi-
omalate, MTX, piroxicam, diclofenac, methylprednisolone, and
prednisolone resulted in significantly decreased levels of IL-6
and CXCL-8/IL-8. Treatment with chloroquine phosphate did
not significantly repress IL-6 and CXCL-8/IL-8 secretion from
human chondrocytes. As already determined by microarray
analysis, treatment with the examined antirheumatic drugs
exclusive of chloroquine phosphate and diclofenac signifi-
cantly repressed the synthesis of CCL-20/MIP-3α in human
chondrocytes. Thus, the gene expression patterns of IL-6,
Figure 6
Enzyme-linked immunosorbent assay (ELISA) analysis of selected rheu- matoid arthritis (RA)-related chondrocyte protein secretions in  response to antirheumatic treatment Enzyme-linked immunosorbent assay (ELISA) analysis of selected rheu-
matoid arthritis (RA)-related chondrocyte protein secretions in 
response to antirheumatic treatment. ELISA analysis confirmed the 
expression profiles of interleukin-6 (IL-6), interleukin-8 (CXCL-8/IL-8), 
and macrophage inflammatory protein-3α (CCL-20/MIP-3α) following 
treatment with azathioprine, gold sodium thiomalate, chloroquine phos-
phate, methotrexate, piroxicam, diclofenac, methylprednisolone, and 
prednisolone on the protein level. The secretion of the cytokines IL-6, 
CXCL-8/IL-8, and CCL-20/MIP-3α was induced in RASFsn-stimulated 
chondrocytes. All examined antirheumatic drugs significantly repressed 
the synthesis of IL-6 and CXCL-8/IL-8 (except for chloroquine phos-
phate) and repressed the synthesis of CCL-20/MIP-3α (except for 
chloroquine phosphate and diclofenac) in human chondrocytes, as 
already determined by microarray analysis. The mean of each triplicate 
well is plotted, and the error bars represent the standard deviation. Sta-
tistical analysis was performed for chondrocytes stimulated with super-
natant of antirheumatically treated rheumatoid arthritis synovial 
fibroblasts (RASFs) compared the untreated condition (*P < 0.05). 
DMARD, disease-modifying antirheumatic drug; NSAID, nonsteroidal 
anti-inflammatory drug; RASFsn, supernatant of untreated rheumatoid 
arthritis synovial fibroblast; SAID, steroidal anti-inflammatory drug.Available online http://arthritis-research.com/content/11/1/R15
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CXCL-8/IL-8, and CCL-20/MIP-3α could be confirmed on
the protein level for all antirheumatic drugs examined.
Discussion
To our knowledge, this is the first genomic study that analysed
the molecular mechanisms of RA-related chondrocyte dys-
function and regeneration in response to treatment with com-
monly used antirheumatic drugs. The study was based on a
previously published in vitro model [18] that induced gene
expression of inflammatory and destructive mediators and
repressed regeneration and matrix formation when chondro-
cyte bead cultures were exposed to the secreted factors of a
well-characterised RASF cell line. RASF-stimulated human
chondrocytes showed a disturbed homeostasis on the molec-
ular level, and the RA-induced gene expression signatures
were considered to be relevant for chondrocyte dysfunction in
RA.
In the present study, we show that the different classes of
drugs exhibited distinct effects on the RA-induced signature in
human chondrocytes. SAIDs were most effective to revert the
molecular changes from the 'diseased' to the 'healthy' pattern.
SAIDs were followed by the DMARDs azathioprine, gold
sodium thiomalate, and MTX, whereas the NSAIDs and the
DMARD chloroquine phosphate had the least effects. Thus,
the molecular data reflect the clinical experience of therapeutic
efficiency. Furthermore, best responses were associated with
a strong suppression of proinflammatory cytokines (IL-6 and
IL-23A), chemokines (CCL-20  and  CXCL-8), and COX-2.
Patterns typical for putative regenerative processes with
downregulation by RASF supernatant and reversion or even
upregulation upon treatment were seen mostly for matrix
genes but also for some factors, which may be inductors of
regeneration like CTGF [30] or CYR-61 [31]. The model that
we applied for this study was selected as a compromise of the
advantages for standardisation, availability, and comparability
with parallel and future testing of different drugs and the dis-
advantage of an in vitro cartilage model and a transformed
RASF cell line.
The RASF cell line certainly does not reflect all aspects of the
in vivo situation and may differ in some aspects from primary
fibroblast cultures of RA patients. Nevertheless, previous stud-
ies have demonstrated that the RASF cell line is a prototype of
activated SFs expressing genes and secreting inflammatory
cytokines (for example, IL-1α, IL-1β, IL-6, IL-11, IL-16, IL-18,
CXCL-1–3/Gro-α-γ, CXCL-8/IL-8, CCL-2/monocyte chem-
oattractant protein-1, basic fibroblast growth factor, and leu-
kaemia inhibiting factor) and matrix-degrading enzymes (for
example, MMP-1, cathepsin-B, and cathepsin-L) associated
with the pathomechanism of RA [14,18,21,22]. The current
setting of the model is focused on the effects of RASFs on
chondrocyte gene expression and excludes the impact of lym-
phocytes and macrophages. This has the advantage that
effects can be precisely attributed to the secretome of RA
fibroblasts. A composed model with several different cell types
would impede functional interpretation of the signature, espe-
cially with respect to the fact that lymphocyte presence and
activity can vary widely from patient to patient and such differ-
ences cannot be addressed without knowing the individual
components. Thus, stepwise development of such signatures
with secretomes of other cell types will account for these addi-
tional effects and will help to interpret, at the end, the effects
of drugs on more complex settings like cocultures of different
cell types or even inflamed tissues. In addition, during recent
years, activated RASFs have been determined to be the key
players of cartilage destruction in RA by perpetuating the
proinflammatory environment in synovial joints and by destroy-
ing cartilage matrix and chondrocyte homeostasis [6,7,15].
Therefore, the model reflects major mechanisms related to RA-
induced cartilage destruction. The alginate bead culture of
chondrocytes was chosen because (a) human chondrocytes
could be cultured batchwise in a phenotype-stabilising sur-
rounding, (b) human chondrocytes could be stimulated batch-
wise with conditioned supernatant of untreated and drug-
treated SFs, and (c) total RNA could be isolated easily from
human chondrocytes after isolation from the alginate.
The different soluble factors secreted by RASFs were consid-
ered to mediate the RA-induced gene expression pattern in
human chondrocytes. Treatment of the RASF cell line with
antirheumatic drugs was shown to repress many of these
proinflammatory factors, with SAIDs being most effective [14].
Therefore, we hypothesise that antirheumatic drugs exert their
effects predominantly on RASFs and their secretome but may
also act on human chondrocytes directly like SAIDs.
This study disclosed SAIDs to be most effective in reverting
RA-induced gene expression in human chondrocytes even
beyond the 'healthy' level, in particular the expression of genes
associated with inflammation/NF-κB (BCL2-A1 and COX-2)
and cytokine/chemokine activity (CXCL-8/IL-8 and IL-6). This
is consistent with the pathway analysis that revealed SAIDs to
target particularly pathways involved in cytokine/chemokine
activity and ECM remodelling. SAID treatment of RASFs has
been shown to repress the synthesis of the proinflammatory IL-
1β and CXCL-8/IL-8 in SFs [14] and thus prevent human
chondrocytes from stimulation by these factors. This is in line
with the clinical application of SAIDs for intra-articular injection
to suppress inflammation and disease activity in the short term.
Consistent with our results, general effects of SAIDs include
inhibition of the synthesis of inflammatory cytokines, reduction
of COX-2 expression, and immune suppression [32-34]. Fur-
thermore, glucocorticoid treatment of RA patients has been
shown to reduce progression of cartilage destruction [35,36].
Thus, SAID therapy is appropriate to achieve rapid suppres-
sion of cartilage destruction and to control symptoms. For
long-term treatment, however, adverse effects provoke serious
problems [32,33].Arthritis Research & Therapy    Vol 11 No 1    Andreas et al.
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Hierarchical clustering and principal components analyses
revealed that the DMARDs azathioprine, gold sodium thioma-
late, and MTX effectively revert the RA-related chondrocyte
gene expression toward the level of 'healthy' expression.
Again, genes involved in inflammation/NF-κB signalling,
cytokine/chemokine activity, immune response, proliferation/
differentiation, and matrix remodelling were predominantly
involved. In accordance with these results, DMARDs are
described to interfere with the disease process, thereby
impeding both the inflammatory and the destructive processes
in RA [2]. Among the DMARDs, MTX is regarded as the most
effective cornerstone of RA therapy [37,38]. Interestingly, only
marginal differences between these three DMARDs were
found although their molecular modes of action differ. Azathi-
oprine is a prodrug that is converted via 6-mercaptopurine by
a series of transferases, kinases, and reductases to exert cyto-
toxicity by DNA incorporation and by inhibiting purine de novo
synthesis [39]. Apparently, RASFs were capable of metabolis-
ing azathioprine into active compounds because cytotoxic
effects of azathioprine on RASFs were determined by MTS
cell proliferation assay (data not shown). MTX is a folate ana-
logue and inhibits methylation processes, and gold sodium thi-
omalate has a complex pharmacology, which recently was
reported to interfere with COX-2 transcription [40,41]. In vivo,
these actions may differ with respect to the cell type (suppres-
sion of lymphocyte proliferation, induction of apoptosis in acti-
vated T cells and monocytes, and inhibition of macrophage
activation) or the kinetics of drug action.
Treatment with chloroquine phosphate, in contrast, resulted in
only minor effects. Chloroquine phosphate is an antimalarial
drug used in the treatment of RA. The exact mechanism of
drug action remains unknown. This study showed that chloro-
quine phosphate repressed the expression of selected RA-
related genes associated with inflammation/NF-κB signalling
and immune response. However, the expression of the major-
ity of RA-related genes was not reproducibly influenced follow-
ing treatment with chloroquine phosphate. In agreement with
the results of this study, chloroquine phosphate has been
described to fail in inhibiting radiographic joint destruction and
to have a relatively slow onset of action when compared with
other DMARDs [34,42].
NSAIDs were described to relieve joint swelling but to have
only minor effects on disease progression and cartilage break-
down. As symptomatic agents, NSAIDs were supposed to
inhibit prostaglandin synthesis by COXs and to help to control
symptoms but to fail to retard or even to heal RA-related joint
destruction [2,3,43]. This is in line with the results from micro-
array analysis that determined only minor effects for diclofenac
and moderate effects for piroxicam on chondrocyte RA-related
gene expression. Piroxicam effects contrasted with those of
diclofenac by substantially repressing COX-2 expression in
chondrocytes. Interestingly, diclofenac treatment of RASFs
has been shown to have minor effects on the expression pro-
file of disease-related genes in SFs [14]. Probably, diclofenac
exerts the RA-related effects on nonfibroblastic cell types that
infiltrate the synovium rather than on SFs [44].
Overall, molecular differences of the various drugs are
reflected by the clinical experience that steroids and the three
DMARDs MTX, azathioprine, and gold sodium thiomalate, but
not chloroquine phosphate or NSAIDs, may be effective in
inhibiting radiographic joint destruction [2,3,34,42,43]. Fur-
thermore, SAIDs are best at suppressing the RA-induced
changes in chondrocytes but are associated with many side
effects. Thus, new therapeutic strategies may focus especially
on molecular effects induced by steroids and the effective
DMARDs but not induced or insufficiently induced by chloro-
quine phosphate and NSAIDs. This qualitative difference of
drugs is best reflected by the expression pattern of COX-2
and several cytokines/chemokines (IL-6,  CXCL-8/IL-8,  IL-
23A, and CCL-20). Inversely, CTGF, CYR-61, and TXNIP are
suppressed by RASFs and reversely induced by the effective
drugs.
Inhibition of the transcription of COX-2 can be considered as
more effective than blocking of the enzyme activity. Transcrip-
tion of COX-2  was highest suppressed compared with all
other genes by SAIDs, which were also the most effective
drugs. Interestingly, prostaglandin E2 synergistically with IL-23
was reported to favour human Th17 expansion [45] and pros-
taglandin E2 may also induce IL-23 in bone marrow-derived
dendritic cells [46]. Here, we find both increased COX-2 and
IL-23 expression in chondrocytes after stimulation by RASFs,
suggesting that chondrocytes may contribute to the develop-
ment of Th17 cells. This T-helper cell type is discussed in sev-
eral aspects of proinflammatory activities and may trigger a
positive feedback loop via IL-6 [47], another candidate found
to be induced in chondrocytes by RASFs and also involved in
the differentiation of Th17 cells. This suggests that cartilage,
when stimulated by RASF supernatant, may contribute to the
proinflammatory network of secondary immune reactions.
With COX-2 (prostaglandins), IL-23A, and IL-6 as inductors
of this process, targeting these molecules could be favoura-
ble.
Concerning induction of regenerative processes, CTGF and
CYR-61 may be potential candidates. CYR-61 is reported as
a regulator of chondrogenesis [31] and belongs to the same
CCN family of molecules as CTGF [48]. However, CTGF is
reported to be involved in many fibrotic processes, including
lung [49] and kidney [50], indicating that only local application
could be advisable.
As long as a causative therapy of RA is not available, the aim
will be to find the appropriate combination of targets that is
most effective in remitting or even healing of RA-related carti-
lage destruction. Since sensitive diagnostic tools to assess
cartilage destruction/repair are rare, in vitro models for theAvailable online http://arthritis-research.com/content/11/1/R15
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evaluation of drug efficiency and the identification of potent
targets are necessary. Candidate genes that evolved in this
study for new therapeutic approaches include suppression of
specific immune responses (COX-2, IL-23A, and IL-6) and
activation of cartilage regeneration (CTGF and CYR-61). Fur-
ther studies are needed to investigate the influence of immune
cells on chondrocytes to complete the molecular effects
induced by inflammatory processes in arthritis.
Conclusion
This in vitro study provides comprehensive insight into the
molecular mechanisms involved in RA-induced chondrocyte
dysfunction and in drug-related chondrocyte regeneration.
Our findings indicate that RA-relevant stimuli result in the
molecular activation of inflammatory and catabolic processes
in human chondrocytes that is again reverted by antirheumatic
treatment. Molecular differences of the various drugs are
reflected by the clinical experience. Furthermore, this study
provides evidence of numerous pharmacological marker
genes to define and induce chondrocyte integrity and regen-
eration, including established genes (COX-2,  CXCR-4,  IL-
1RN,  IL-6/8,  MMP-10/12, and TLR-2) and new genes
(ADORA2A, BCL2-A1, CTGF, CXCR-7, CYR-61, HSD11B-
1, IL-23A, MARCKS, MXRA-5, NDUFA4L2, NR4A3, SMS,
STS, TNFAIP-2, and TXNIP). Candidate genes that evolved in
this study for new therapeutic approaches include suppres-
sion of specific immune responses (COX-2, IL-23A, and IL-6)
and activation of cartilage regeneration (CTGF and CYR-61).
Thus, from the molecular point of view, the present study helps
to elucidate the role of chondrocytes during cartilage destruc-
tion in RA and during antirheumatic therapy and may contrib-
ute to the development of novel therapeutic chondro-
protective agents and strategies.
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